Tarpeyo (budesonide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:	**FIRST NAME:**	
PHONE NUMBER:	**DATE OF BIRTH:**	
STREET ADDRESS:		
CITY:	**STATE:**	**ZIP CODE:**
PATIENT INSURANCE ID NUMBER:		

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	**FIRST NAME:**	
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**	
NPI NUMBER:	**DEA NUMBER:**	
PHONE NUMBER:	**FAX NUMBER:**	
STREET ADDRESS:		
CITY:	**STATE:**	**ZIP CODE:**
REQUESTER (if different than prescriber):	**OFFICE CONTACT PERSON:**	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Tarpeyo (budesonide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ **YES** (if yes, complete below) ☐ **NO**		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ Primary immunoglobulin A nephropathy (IgAN), ☐ Other diagnosis: _____ ICD-10 Code(s):	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Will the patient be using the drug as a part of the clinical trial? ☐ **Yes** ☐ **No**

Was the patient diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed via renal biopsy? (Documentation required) ☐ **Yes** ☐ **No**

Is the patient at risk of rapid disease progression? (Documentation required)? ☐ **Yes** ☐ **No**

Were other causes of immunoglobulin A nephropathy (IgAN), such as but not limited to viral causes, inflammatory bowel disease, ruled out? ☐ **Yes** ☐ **No**

Has the patient been on a maximum tolerate dose of an angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker for at least 3-months? (Documentation required)
☐ **Yes** ☐ **No**

If no to the question above, does the patient have an absolute contraindication to angiotensin converting enzyme (ACE) inhibitor or a Angiotensin II receptor blocker? (Documentation required)
☐ **Yes** ☐ **No**

Does the patient have proteinuria of at least 1 gram per day? (Documentation required)
☐ **Yes** ☐ **No**

Does the patient have an estimated eGFR of at least 35 mL/min/1.73 m2? ☐ **Yes** ☐ **No**

Does the patient have a history of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid (e.g., methylprednisolone, prednisone) (documentation required)? ☐ **Yes** ☐ **No**

Will Tarpeyo (budesonide) be used in combination with Voyxact (sibeprenlimab), Filspari (sparsentan), Fabhalta (iptacopan), or Vanrafia (atrasentan)? ☐ **Yes** ☐ **No**

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Tarpeyo (budesonide)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Will Tarpeyo (budesonide) be used in combination with Soliris(eculizumab) or Ultomiris(ravulizumab), Empaveli(pegcetacoplan) or Voydeya(danicopan) ? ☐ **Yes** ☐ **No**

Is Filspari (sparsentan) being prescribed by, or in consultation with, a nephrologist? ☐ **Yes** ☐ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company